Phase 2 N=22 Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI
Epilepsy · SUDEP
Primary: Study Recruitment Rate — 3.8 participants/3 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=52 Effect of Opioids on Ventilation in Children With Obstructive Sleep Apnea
Respiratory Depression · Obstructive Sleep Apnea
Primary: Respiratory Depression Following Opioids — -38.1; -37.1 percentage of change from baseline
N/A N=54 Ketamine Infusion and Hypoventilation
Hypoventilation
Primary: Intraoperative Hypoventilation — 1.2; 65 % time
Phase 1 N=55 Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation
Hypercapnia · Ventilatory Depression
Primary: Part 1 - Minute Ventilation at the 55 mm Hg End Tidal Carbon Dioxide (CO2) Point (VE55) on Day 1 for Oxycodone Combined With Midazolam and Oxycodone Alone. — 21.9; 24.1…
N/A N=15 The Effects of Ketamine on Respiratory Stimulation and Transpulmonary Pressures
Mechanical Ventilation · Airway Patency · Respiratory Depression
Primary: Inspiratory Airflow — 0.36; 0.47; 0.44 L/s
Phase 1 N=27 Effect of Selective Serotonin Reuptake Inhibitors (SSRIs) and an Opioid on Ventilation
Hypercapnia · Ventilatory Depression
Primary: Minute Ventilation at 55mm Hg End Tidal CO2 (VE55) Under Hyperoxic Conditions on Day 21 — 20.2; 21.2; 26.7 L/min — p=<0.001
N/A N=1,495 PRediction of Opioid-induced Respiratory Depression In Patients Monitored by capnoGraphY
Respiratory Depression
Primary: Determine Number of Subjects With RD While on Opioid Therapy — 655; 840 Participants
N/A N=211 Detecting Post-Operative Respiratory Depression in Children
Respiratory Depression
Primary: Abnormal ETCO2 Values, Abnormal Pulse Oximetry Values, and Staff Interventions — 56; 58; 8; 15 participants
Phase 3 N=580 Effect of Intravenous Acetaminophen on Postoperative Opioid-related Complications
Postoperative Pain
Primary: Duration of Hypoxemia — 0.7; 1.1 min/h — p=0.29
Phase 4 N=14 Sleep and Breathing in the General Population - Chemical Stimuli
Sleep-disordered Breathing
Primary: The Central Apnea-hypopnea Index — 14.1; 29.9 events per hour
N/A N=11 Sedation in Patients at Risk for Upper Airway Collapse
Obstructive Sleep Apnea
Primary: Respiratory Disturbance Index — 57.52; 21.32 events per hour
Phase 4 N=6,824 Applying Best Clinical Practices to Patients at High Risk of Respiratory Complications
Respiratory Complication · Obstructive Sleep Apnea
Primary: Time to "Fitness for Discharge" From the Recovery Room — 165.64; 154.60 Minutes
N/A N=14 Role of Endorphins in Perception of Dyspnea With Resistive Loading in Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Primary: Intensity of Breathlessness — 77; 83 units on a scale — p=.0004
Phase 1 N=45 A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.
Opioid Use Disorder
Primary: Number of Participants With Increased End-tidal Carbon Dioxide (EtCO2) of at Least 10 mmHg Compared to Baseline or > 50 mmHg on Day 1 — 0; 0 Participants
Phase 4 N=40 Effect of Neuromuscular Blockade and Reversal on Breathing
Respiratory Insufficiency
Primary: Breathing Increase Due to a Reduction in Inspired Oxygen Saturation (Hypoxic Ventilatory Response) — 0.66; 0.43; 0.54; 0.34 L/min/% desaturation
N/A N=10 Phamacological Reversal of Airway Instability During Sedation
Upper Airway Obstruction
Primary: AHI - Apnea Hypopnea Index — 14.5; 27.9; 11.3; 12.1 events per hour
Phase 2 N=54 Effectiveness of Continuous Negative External Pressure in Preventing Upper Airway Impairment During Routine Colonoscopy
Airway Obstruction · Apnea · Hypopnea
Primary: RI Events in the cNEP Group Compared to the no cNEP Group, Where RI is Defined as Either: i Oxygen Saturation < 90% or ii. Apneas/Hypopneas of > 15 Sec Duration i…
Phase 2 N=36 Efficacy and Safety of Dexmedetomidine During Non-Invasive Positive Pressure Ventilation
Acute Respiratory Failure
Primary: Tolerability of NIV as Assessed by an NIV Tolerance Score — 99; 67 percentage of time spent tolerant to NIV — p=0.54
N/A N=49 Prevention of Opioid-Induced Hypoxemia
Non-cardiac Surgery
Primary: Time-weighted Average of SpO2 Below a Threshold of 90% — 0.29; 0.11; 0.16; 0.10 % of SpO2 — p=0.120
Phase 4 N=61 Effects of Deep Neuromuscular Blockade on Intraoperative Respiratory Mechanics
Laparoscopic Renal Surgery · Laparoscopy · Muscle Relaxation
Primary: Thoracopulmonary Compliance — 51.9; 52.3; 34.6; 31.9 ml/cmH2O
Phase 4 N=62 Comparison of Deep Extubation During Emergence Using Desflurane or Desflurane With Remifentanil in Patients Undergoing General Anesthesia
Deep Extubation
Primary: Awakening Time — 10; 7 minutes
Phase 1 N=25 Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)
Insomnia
Primary: Mean Arterial Oxygen Saturation (SaO2) During Total Sleep Time — 93.38; 92.99 Percentage of Oxygen Saturation
Phase 3 N=26 Dexmedetomidine to Treat Bariatric Surgery-associated Pain
Obesity
Primary: Pain Scores (Numerical Rating Scale 0-10) Using the Faces Pain Scale-Revised — 5; 3.4 Units on a scale
N/A N=16 Effect of Inhaled Fentanyl on Dyspnea and Exercise Tolerance in Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Primary: Dyspnea Intensity Measured by the 10-point Borg Scale During Cycle Exercise — 2.6; 2.0 units on a scale
N/A N=21 Effectiveness of Adaptive Servoventilation (ASV) in Patients With Central Sleep Apnea Due to Chronic Opioid Use
Obstructive Sleep Apnea · Central Sleep Apnea (Diagnosis) · Chronic Opioid Use
Primary: Apnea Hypopnea Index (AHI) — 2.5; 16.3 events/hour
N/A N=90 Remifentanil Versus Dexmedetomidine for Post-Cardiac Surgery Patients With Noninvasive Ventilation Intolerance
Cardiac Surgery
Primary: Number of Participants With NIV Failure — 10; 8 Participants — p=0.831
Phase 4 N=50 Alternative Sedation During Bronchoscopy
Sedation
Primary: Decreased Minute Ventilation — 0.736; 0.764 percentage of baseline — p=<0.0001
N/A N=39 Bupivacaine Versus Ropivacaine on Diaphragmatic Motility and Ventilatory Function
Paresis
Primary: Forced Expiratory Volume at 1 Second (% Change From Baseline) — -22.4; -29.4 percentage of change from baseline
Phase 4 N=260 Sugammadex vs Placebo to Prevent Residual Neuromuscular Block
General Surgery
Primary: Decreased Minute Ventilation (MV) — 20; 26 Participants
N/A N=52 Behavioral Activation-Rehabilitation to Improve Depressive Symptoms & Physical Function After Acute Respiratory Failure
Respiratory Insufficiency · Depression · Rehabilitation
Primary: Feasibility Measure Per Participant — 0.8 proportion of intended visits